Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)

Swathi Lingam, Nopnithi Thonghin, Robert C. Ford

Research output: Contribution to journalArticlepeer-review


Ivacaftor is a potentiator of the CFTR chloride channel and is in worldwide clinical use for the chronic treatment of cystic fibrosis in patients. There is evidence that the bioavailability of ivacaftor in the body may be influenced by the multi-drug exporter P-glycoprotein. Here we have employed purified and reconstituted P-glycoprotein to study its interaction with ivacaftor as well as the ability of the drug to compete with a known transported substrate of the protein. We find that ivacaftor stimulates the ATPase activity of the purified protein and can compete with the transport of the fluorescent substrate Hoechst 33342. These findings lead us to conclude that ivacaftor is very likely an efficiently transported substrate of P-glycoprotein. Evidence for state-dependent binding of ivacaftor was obtained using a fluorescent, cysteine-reactive reporter dye. The quiescent, nucleotide-free state in the P-glycoprotein transport cycle appears to bind ivacaftor strongly.

Original languageEnglish
Article number17481
JournalScientific Reports
Issue number1
Early online date13 Dec 2017
Publication statusPublished - Dec 2017


Dive into the research topics of 'Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)'. Together they form a unique fingerprint.

Cite this